Very early mobilisation within 24 hours of stroke results in a less favourable outcome at 3 months [commentary 3]  by Brauer, Sandra
Appraisal Critically Appraised Papers220CommentaryThe AVERT trial shows that a theoretically plausible intervention
– intensive and very earlymobilisation of stroke patients – begun as
soonaspossible after admission, is not better thanexistingprotocols
and may actually be harmful. This implies that the 22 existing
guidelines worldwide on early stroke rehabilitation need to be
rewritten. In fact, the AVERT trial suggests that very early
mobilisation of stroke patients should be restricted to a few times
in theﬁrst 24hoursand limited to small doses of 10minutesatmost.
This restriction is particularly recommended for stroke patients
with very severe neurological impairments (National Institutes
of Health Stroke Scale > 16) and patients with haemorrhagic
stroke.
The AVERT trial raises the question: why is applying a higher
dose of out-of-bed therapy, slightly earlier, more harmful than a
lower dose of shorter duration? Is the impaired regional cerebral
blood ﬂow in penumbral areas sensitive to orthostatic variation?1,2
It may be assumed that, especially in severe and haemorrhagic
strokes, the cerebrovascular autoregulation needed to sustain
sufﬁcient regional cerebral blood ﬂow is impaired.3,4 High doses of
long-duration mobilisation very early after stroke, which often
result in tired and drowsy patients slumping in their chairs, may
further reduce the regional cerebral blood ﬂow in critical
penumbral and oligaemic brain areas, thus increasing neurological
damage. Further research of patients with (hyper)acute stroke isnowneeded into the longitudinal association between dependence
on body and head position and cardiac output on the one hand, and
impaired cerebral haemodynamics and reduced cerebral perfusion
on the other.
Although the AVERT trial suffers from some minor methodo-
logical problems such as contamination, as the usual care group
started mobilisation earlier each year, the indirect message of
this ground-breaking trial is that sufﬁciently powered [10_TD$DIFF]Phase III
trials are possible in complex interventions such as stroke
rehabilitation.
Provenance: Invited. Not peer-reviewed.
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http://dx.doi.org/10.1016/j.jphys.2015.07.012CommentaryAfter stroke, clinical practice guidelines recommend manage-
ment in an acute stroke unit because there is strong evidence to
indicate that this reduces death and disability.1 Early mobilisation
is proposed to be a contributing factor to these better outcomes;2
however, this recommendation is not underpinned by evidence, [1_TD$DIFF]
and nor is early mobilisation clearly deﬁned. This paper presents
the primary results of the AVERT Trial, a large Phase III trial, which
provides this evidence.
This study is a landmark clinical trial for physiotherapy for
numerous reasons: it investigates physiotherapy intervention
sequentially, with preliminary evidence gained across earlier
Phase I and Phase II trials; it is amassive trial involving 56 hospitals
across ﬁve countries, thus, ﬁndings are highly generalisable and
provide a rich dataset for ongoing analysis; it shows that a
complex, multidisciplinary intervention in stroke care can be
undertaken in a trial considered high quality in terms of design,
adherence, management and analysis; and it shows these trials can
be performed and led by physiotherapists.
The results show that very early mobilisation reduces the odds
of a favourable outcome at 3 months compared with usual care,
which is contrary to our assumptions. The intervention arm
received earlier mobilisation than the control (by 4.8 hours). Some
may query the clinical impact of this difference, but there was a
resultant difference in the primary outcome. To understand theimportance of the timing, type and amount of early mobilisation,
further analysis is required to investigate the change in usual care
over the 8 years of the trial and the dose-response analysis.
Investigation of these results will provide the evidence to inform
optimal stroke unit care.
Some may be disappointed that the primary results are not in
favour of very early mobilisation. They show that the phrase ‘more
is better’ might not apply in this early timeframe. This is an
important ﬁnding, despite being in a possibly surprising direction,
and it challenges our assumptions, forces us to rethink and
consider our practice more deeply.
Provenance: Invited. Not peer-reviewed.
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http://dx.doi.org/10.1016/j.jphys.2015.07.014Author’s response: where to next?The AVERT trial was a labour of love for the hundreds of
clinicians, researchers and patients involved. The collective vision
of research excellence and discovery, of building the stroke
rehabilitation and recovery evidence base was clear and ever
present. So too was the shared value of collaboration, of
participating in something that extended beyond our own national
boundaries. It has been an exciting and demanding experience, and
we have all learnt a lot[2_TD$DIFF].
These early, primary results from the trial have been surprising
to many. Increasingly, over the last decade, early rehabilitation
and mobilisation has been recommended, despite limited, albeit
positive, evidence.1 Over the long course of AVERT we witnessed
(and more importantly, measured) a shift in practice to earlierintervention in usual care. It is unknown whether this reﬂects
within-trial ‘contamination’ or the more global shift in practice.
Large, pragmatic trials take time and AVERT took far longer than
our collective wisdom suggested. We have indeed shown that
global trials can be done, but it was tough. Our new insights into the
major challenges of these trials cover planning for timely trial
completion,which contains costs and [3_TD$DIFF]maintains the trial’s relevance
in a shiftingworld, and the need for better fundingmechanisms and
broader collaboration to support global rehabilitation trials.
Despite, or perhaps because of, the shifting practice landscape,
the results of AVERT are clear: doing too much too soon interferes
with the recovery process. As further results emerge, clearer
guidance for practice will be possible. The ‘who’, ‘when’ and ‘how
